Targacept Scientists to Present at Neuroscience 2012

Targacept TRGT, a clinical-stage biopharmaceutical company developing novel NNR Therapeutics ™, today announced that its scientists are scheduled to make several poster presentations at Neuroscience 2012, the 42nd annual meeting of the Society for Neuroscience, being held in New Orleans from October 13 through October 17, 2012. The data to be presented are based on research conducted over the last year and provide additional support for the potential of NNR Therapeutics as a novel treatment approach for multiple diseases and disorders. Targacept scientists are scheduled to make a total of nine presentations at the conference, providing data for compounds such as: AZD1446, a product candidate being pursued in collaboration with AstraZeneca, scheduled for Tuesday, October 16 at 10:00 a.m. Eastern Time; and TC-8831, a late preclinical product candidate for Parkinson's disease or L-dopa-induced dyskinesia, scheduled for Sunday, October 14 at 8:00 a.m. and 10:00 a.m. Eastern Time. A complete list of the presentations is available upon request.